Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health Companies Inc. (NYSE/TSX: BHC) has appointed Thomas J. Appio as CEO and announced its leadership team and Board of Directors. Following the IPO of Bausch + Lomb, Joseph C. Papa will transition to chairman and CEO of Bausch + Lomb. The new executive team comprises experienced leaders, including Thomas Vadaketh as CFO and Seana Carson as General Counsel. Richard Mulligan, Ph.D., was appointed to the Board. The full separation of Bausch + Lomb is expected to finalize on May 10, 2022, with shares trading under the symbol 'BHC'.

Bausch + Lomb Corporation, a subsidiary of Bausch Health (NYSE/TSX: BHC), has announced the pricing of its initial public offering (IPO) of 35 million common shares at $18.00 each. Bausch + Lomb will not receive the proceeds from this offering, as it is being conducted by the Selling Shareholder. The shares are set to trade on the NYSE and TSX under the ticker symbol 'BLCO' starting May 6, 2022. Following the IPO, Bausch Health will retain around 90% of Bausch + Lomb's shares, decreasing to 88.5% if the underwriters' over-allotment option is fully exercised.

Bausch Health and Novaliq announced that their investigational treatment NOV03 successfully met primary endpoints in two pivotal Phase 3 trials for treating dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The latest trial results demonstrated significant improvements in total corneal fluorescein staining and eye dryness scores at day 57. With potential FDA submission in Q2 2022, NOV03 could become the first pharmaceutical therapy available in the U.S. targeting this common ocular condition affecting approximately 18 million Americans.

Bausch Health Companies (NYSE/TSX: BHC) will announce its first-quarter financial results on May 10, 2022. A conference call and live webcast will be held at 8:00 a.m. ET to discuss these results and provide a business update. Investors can access materials through the Investor Relations section of the Bausch Health website before the call.

Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies (NYSE/TSX: BHC), has announced its initial public offering (IPO), offering 35 million common shares with an expected price range of $21 to $24 per share. A 30-day option for underwriters to purchase an additional 5.25 million shares is also planned. Post-IPO, Bausch Health will hold approximately 90% of Bausch + Lomb's shares. The IPO aims for listing on the NYSE and TSX under the ticker symbol 'BLCO'. Bausch + Lomb will not receive any IPO proceeds.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced an arrangement agreement to facilitate the separation of its eye health business, Bausch + Lomb Corporation. This agreement outlines terms for transferring shares of Bausch + Lomb to Bausch Health shareholders post-IPO. The arrangement is subject to various conditions, including regulatory approvals and tax opinions to ensure a tax-free transaction. A special shareholder meeting will be convened after the IPO for further consideration. Completion of the process is contingent upon meeting all aforementioned conditions.

Bausch + Lomb, a leading eye health business of Bausch Health Companies (NYSE/TSX: BHC), will showcase 13 scientific poster presentations at the ARVO annual meeting from May 1-4, 2022. Presentations will include pivotal Phase 3 trial results for NOV03, an investigational treatment for dry eye disease, and data on XIPERE® for macular edema associated with uveitis. The company emphasizes its commitment to research and innovation in ophthalmology, aiming to provide valuable insights for eye care professionals.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced four poster presentations at the Florida Society of Dermatology Physician Assistants (FSDPA) New Wave Dermatology Conference from April 28 to May 1, 2022. The presentations will include new clinical data on ARAZLO^® (tazarotene) lotion for truncal acne, marking its first open-label clinical study for this condition. Additional data on DUOBRII^®, JUBLIA^®, and SILIQ^® will also be shared, highlighting the company's commitment to advancing dermatological treatments.

Bausch Health (BHC) and Novaliq GmbH announced positive results from the pivotal Phase 3 trial (GOBI) for NOV03, a novel eye drop treatment for dry eye disease associated with Meibomian gland dysfunction. The study involved 597 participants and demonstrated that NOV03 met both primary endpoints: a significant decrease in total corneal fluorescein staining and improved eye dryness scores at day 57 (P<0.001). The treatment was well tolerated with low adverse event rates. The companies plan to submit for FDA approval in Q2 2022, potentially addressing a significant unmet medical need.